Literature DB >> 11881111

Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.

W Wienen1, H J Schierok.   

Abstract

The effects of telmisartan and hydrochlorothiazide (HCTZ) alone and in combination on blood pressure (BP) and renal excretory function were investigated in male spontaneously hypertensive rats (SHR) after oral administration for five consecutive days. Four treatments were studied: vehicle (0.5% Natrosol), telmisartan 3 mg/kg, HCTZ 10 mg/kg, and telmisartan 3 mg/kg+HCTZ 10 mg/kg. The effects on BP and heart rate were studied in 40 SHRs (10 animals per group) using an implanted telemetry device. Renal excretory function was assessed in 76 SHRs (18 animals per group, of which nine were used for urine sampling and nine for blood sampling). The telmisartan/HCTZ combination produced the greatest reductions in trough DBP (-44+/-1.5 mmHg), SBP (-60+/-1.9 mmHg) and mean BP (mBP; -53+/-1.7 mmHg) after five days of therapy (p<0.05 vs. vehicle and vs. telmisartan). Telmisartan monotherapy also decreased DBP, SBP and mBP significantly (p<0.05), but only minor BP fluctuations occurred in SHRs receiving HCTZ or vehicle. Telmisartan/HCTZ elevated heart rate by approximately 12 beats per minute (p<0.05 vs.control). Significant increases in urine volume and Na+, Cl, K+, creatinine and glucose excretion were observed with HCTZ treatment (p<0.01). Telmisartan/HCTZ also promoted renal water and electrolyte excretion (p<0.01); the diuretic effect appeared to be greater with the combination than with HCTZ alone, and there was some attenuation of urinary K+ loss. Elevated blood urea nitrogen levels were observed only in HCTZ-treated SHRs. These results indicate that the antihypertensive efficacy of telmisartan in SHRs is augmented by co-administration with HCTZ. The combination did not affect renal excretory function, with the exception of an increase in blood urea nitrogen and a possible amelioration of HCTZ-related K+ depletion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11881111     DOI: 10.3317/jraas.2001.013

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  6 in total

1.  Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.

Authors:  Tomoko Kurata; Violeta Lukic; Miki Kozuki; Daisuke Wada; Kazunori Miyazaki; Nobutoshi Morimoto; Yasuyuki Ohta; Kentaro Deguchi; Toru Yamashita; Nozomi Hishikawa; Kosuke Matsuzono; Yoshio Ikeda; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2014-01-17       Impact factor: 6.829

Review 2.  Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.

Authors:  Caroline Fenton; Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.

Authors:  Greg L Plosker; William B White
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

Authors:  Marc P Maillard; Michel Burnier
Journal:  Vasc Health Risk Manag       Date:  2007

5.  Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats.

Authors:  Sawsan A Sadek; Laila A Rashed; Amira M Bassam; Eman S Said
Journal:  J Adv Res       Date:  2014-11-20       Impact factor: 10.479

6.  The Antihypertensive Effect of Quercetin in Young Spontaneously Hypertensive Rats; Role of Arachidonic Acid Metabolism.

Authors:  Fawzy Elbarbry; Khaled Abdelkawy; Nicholas Moshirian; Ahmed M Abdel-Megied
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.